ES2550094T3 - Composiciones de N-acetilcisteína y métodos de tratamiento y de prevención de la toxicidad de los medicamentos - Google Patents
Composiciones de N-acetilcisteína y métodos de tratamiento y de prevención de la toxicidad de los medicamentos Download PDFInfo
- Publication number
- ES2550094T3 ES2550094T3 ES02725376.4T ES02725376T ES2550094T3 ES 2550094 T3 ES2550094 T3 ES 2550094T3 ES 02725376 T ES02725376 T ES 02725376T ES 2550094 T3 ES2550094 T3 ES 2550094T3
- Authority
- ES
- Spain
- Prior art keywords
- acetylcysteine
- amount
- acetaminophen
- prevention
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title abstract 6
- 229960004308 acetylcysteine Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title 1
- 206010070863 Toxicity to various agents Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 18
- 229960005489 paracetamol Drugs 0.000 abstract description 9
- 230000037396 body weight Effects 0.000 abstract description 2
- 206010019851 Hepatotoxicity Diseases 0.000 abstract 2
- 206010029155 Nephropathy toxic Diseases 0.000 abstract 2
- 230000007686 hepatotoxicity Effects 0.000 abstract 2
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 2
- 230000007694 nephrotoxicity Effects 0.000 abstract 2
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013417 toxicology model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US833228 | 1992-02-10 | ||
| US28060001P | 2001-03-30 | 2001-03-30 | |
| US280600P | 2001-03-30 | ||
| US09/833,228 US6566401B2 (en) | 2001-03-30 | 2001-04-11 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| PCT/US2002/009442 WO2002078627A2 (en) | 2001-03-30 | 2002-03-28 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2550094T3 true ES2550094T3 (es) | 2015-11-04 |
Family
ID=26960383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02725376.4T Expired - Lifetime ES2550094T3 (es) | 2001-03-30 | 2002-03-28 | Composiciones de N-acetilcisteína y métodos de tratamiento y de prevención de la toxicidad de los medicamentos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6566401B2 (enExample) |
| EP (1) | EP1379232B1 (enExample) |
| JP (3) | JP2005508840A (enExample) |
| CN (1) | CN100464743C (enExample) |
| AU (1) | AU2002255942B2 (enExample) |
| BR (1) | BR0208563A (enExample) |
| CA (1) | CA2442168C (enExample) |
| ES (1) | ES2550094T3 (enExample) |
| IL (2) | IL158181A0 (enExample) |
| MX (1) | MXPA03008904A (enExample) |
| NZ (1) | NZ528478A (enExample) |
| RU (1) | RU2291689C2 (enExample) |
| WO (1) | WO2002078627A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662863B2 (en) * | 2003-06-09 | 2010-02-16 | Alan Andrews | Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion |
| ES2819303T3 (es) | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| RU2302236C2 (ru) * | 2005-09-09 | 2007-07-10 | Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) | Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции |
| US20070098790A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN102088965B (zh) * | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| JP2012520342A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート |
| WO2010132864A1 (en) * | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| US20120122787A1 (en) * | 2009-07-10 | 2012-05-17 | Rong Li | Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases |
| CN102573463A (zh) * | 2009-07-15 | 2012-07-11 | 小利兰·斯坦福大学托管委员会 | N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 |
| DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| US20140135396A1 (en) * | 2011-07-05 | 2014-05-15 | Beth Israel Deaconess Medical Center, Inc. | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide |
| US8747894B2 (en) | 2012-05-08 | 2014-06-10 | Alpex Pharma S.A. | Effervescent compositions containing N-acetylcysteine |
| WO2013175479A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| PE20180026A1 (es) | 2015-01-27 | 2018-01-09 | Florengale Llc | Composicion topica curativa |
| EP3302580B1 (en) | 2015-05-27 | 2021-01-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Compositions and methods for reducing the risk of post-imaging pancreatitis |
| JP7074663B6 (ja) * | 2015-05-28 | 2022-08-01 | ベイラー カレッジ オブ メディスン | グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果 |
| JP7311267B2 (ja) * | 2016-01-11 | 2023-07-19 | エゲティス・セラピューティクス・アーベー | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| CN115154619B (zh) * | 2016-02-04 | 2025-11-28 | 西泽普研究与发展有限责任公司 | 受控释放和层状的环糊精包合物媒介物 |
| EA201991331A1 (ru) | 2016-12-15 | 2019-11-29 | N-ацетилцистеин для применения в качестве антибактериального агента | |
| US11040007B2 (en) * | 2017-01-24 | 2021-06-22 | Woosung Pharmaceutical Co., Ltd. | Injection composition containing acetaminophen |
| WO2020129509A1 (ja) * | 2018-12-21 | 2020-06-25 | 富士フイルム株式会社 | 光毒性または光アレルギーの測定方法および上記測定方法において使用するための試薬 |
| US11590090B2 (en) | 2019-09-14 | 2023-02-28 | Anzen Pharmaceuticals, LLC | Acetaminophen formulation with protection against toxic effects of overdose |
| GB2588172B (en) * | 2019-10-11 | 2023-05-24 | Blackhawk Partners Ltd | A pharmaceutical composition comprising cannabinoid |
| CN113288890B (zh) * | 2021-06-21 | 2022-02-22 | 南方医科大学南方医院 | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 |
| US12357667B2 (en) | 2021-07-28 | 2025-07-15 | Pono Lifestyle, Llc | Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins |
| EP4238559A1 (en) | 2022-03-04 | 2023-09-06 | Centre Hospitalier Universitaire de Caen Normandie | Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US547457A (en) * | 1895-10-08 | Trolley-track | ||
| IT1141406B (it) * | 1980-04-01 | 1986-10-01 | Dob Far Spa | Sali della cefapirina con aminoacidi |
| FR2519988B1 (fr) * | 1982-01-20 | 1985-06-14 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
| DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
| CA1339256C (en) * | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
| IT1248995B (it) * | 1990-06-26 | 1995-02-11 | Italfarmaco Spa | Composizioni farmaceutiche a base di sali ferrosi |
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
| US5475757A (en) * | 1994-06-07 | 1995-12-12 | At&T Corp. | Secure data transmission method |
| AU4399396A (en) * | 1994-12-19 | 1996-07-10 | Russinsky Limited | Compounds |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| FR2744917B1 (fr) | 1996-02-16 | 1998-04-10 | Kouchner Gerard | Composition therapeutique a base d'acetaminophene |
| US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| US5962421A (en) * | 1996-05-16 | 1999-10-05 | Zambon, S.A. | Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases |
| KR20010020611A (ko) * | 1997-07-01 | 2001-03-15 | 아테로제닉스, 인코포레이티드 | 항산화제에 의한 과증식질병 치료의 향상 |
| EP1141318B1 (en) * | 1999-01-04 | 2006-07-05 | Innovata PLC | P450 / acetaminophen gdept for cancer treatment |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
-
2001
- 2001-04-11 US US09/833,228 patent/US6566401B2/en not_active Expired - Lifetime
-
2002
- 2002-03-28 CN CNB028077334A patent/CN100464743C/zh not_active Expired - Fee Related
- 2002-03-28 RU RU2003131876/15A patent/RU2291689C2/ru not_active IP Right Cessation
- 2002-03-28 AU AU2002255942A patent/AU2002255942B2/en not_active Expired
- 2002-03-28 EP EP02725376.4A patent/EP1379232B1/en not_active Revoked
- 2002-03-28 MX MXPA03008904A patent/MXPA03008904A/es active IP Right Grant
- 2002-03-28 ES ES02725376.4T patent/ES2550094T3/es not_active Expired - Lifetime
- 2002-03-28 CA CA2442168A patent/CA2442168C/en not_active Expired - Lifetime
- 2002-03-28 NZ NZ528478A patent/NZ528478A/en not_active IP Right Cessation
- 2002-03-28 WO PCT/US2002/009442 patent/WO2002078627A2/en not_active Ceased
- 2002-03-28 IL IL15818102A patent/IL158181A0/xx unknown
- 2002-03-28 JP JP2002576895A patent/JP2005508840A/ja active Pending
- 2002-03-28 BR BRPI0208563-1A patent/BR0208563A/pt not_active IP Right Cessation
- 2002-11-04 US US10/287,175 patent/US7723389B2/en not_active Expired - Fee Related
-
2003
- 2003-09-30 IL IL158181A patent/IL158181A/en active IP Right Grant
-
2011
- 2011-08-01 JP JP2011168224A patent/JP2011225610A/ja active Pending
-
2014
- 2014-10-06 JP JP2014205506A patent/JP2015078185A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2291689C2 (ru) | 2007-01-20 |
| EP1379232B1 (en) | 2015-07-29 |
| MXPA03008904A (es) | 2005-03-07 |
| EP1379232A4 (en) | 2008-04-23 |
| BR0208563A (pt) | 2006-02-21 |
| US20030069311A1 (en) | 2003-04-10 |
| IL158181A0 (en) | 2004-03-28 |
| CA2442168C (en) | 2012-05-29 |
| JP2005508840A (ja) | 2005-04-07 |
| JP2015078185A (ja) | 2015-04-23 |
| CA2442168A1 (en) | 2002-10-10 |
| US20020142991A1 (en) | 2002-10-03 |
| WO2002078627A3 (en) | 2003-09-18 |
| AU2002255942B2 (en) | 2007-07-05 |
| RU2003131876A (ru) | 2005-04-10 |
| WO2002078627A2 (en) | 2002-10-10 |
| EP1379232A2 (en) | 2004-01-14 |
| IL158181A (en) | 2012-04-30 |
| CN100464743C (zh) | 2009-03-04 |
| CN1507350A (zh) | 2004-06-23 |
| JP2011225610A (ja) | 2011-11-10 |
| US7723389B2 (en) | 2010-05-25 |
| US6566401B2 (en) | 2003-05-20 |
| NZ528478A (en) | 2007-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| MY118164A (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
| JP2572768B2 (ja) | レボドパメチルエステルを有効成分とするパ−キンソン病治療剤 | |
| RU2355700C2 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| CN100464743C (zh) | 治疗和预防药物中毒的n-乙酰半胱氨酸组合物 | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| AU765038B2 (en) | Method for the treatment of insomnia | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| IE64403B1 (en) | Agents for Blocking Endothelin Derived Relaxing Factor | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| RU2008113439A (ru) | Композиции с замедленным высвобождением лекарственного средства | |
| TNSN04095A1 (en) | Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus | |
| BR0211198A (pt) | Composições farmacêuticas e seu uso | |
| OA12806A (en) | Novel perindopril salt and pharmaceutical compositions containing same. | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
| ES2207751T3 (es) | Derivado de adamantanaminas para combatir los virus de la familia borna viridae. | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| ES2078019T3 (es) | Amidas de alcanoil l-carnitina con aminoacidos y composiciones farmaceuticas que las contienen para promover regeneracion del tejido nervioso, inhibir degeneracion neuronal, mejorar el proceso de aprendimiento y memoria y para el tratamiento de coma. | |
| US3699229A (en) | 2-oxo-5-phenyl-4-oxazolidinone as an anti-depressant agent |